Anthracycline Dose, Myocardial Injury, and Change in Left Ventricular Function in the Cardiac CARE Trial
Hs-cTnI levels were not associated with cumulative anthracycline dose and were only weakly associated with LVEF decline at 6 months. These findings suggest that mild myocardial injury, as reflected by hs-cTnI elevation, may not reliably predict subsequent cardiac dysfunction following anthracycline chemotherapy.
Authors
- Peter Henriksen (ORCID: https://orcid.org/0000-0003-4974-0344)
- Ninian N. Lang (ORCID: https://orcid.org/0000-0001-8441-6887)
- Krithika Loganath (ORCID: https://orcid.org/0000-0003-1378-306X)
- Nicholas L. Mills (ORCID: https://orcid.org/0000-0003-0533-7991)
- Peter S Hall (ORCID: https://orcid.org/0000-0001-6015-7841)
- Shruti Joshi (ORCID: https://orcid.org/0000-0001-9874-6211)
- Malcolm Gracie Semple (ORCID: https://orcid.org/0000-0001-9700-0418)
- Trisha Singh (ORCID: https://orcid.org/0000-0002-4314-9935)
- Kuan Ken Lee (ORCID: https://orcid.org/0000-0003-3404-4098)
- Olga Oikonomidou (ORCID: https://orcid.org/0000-0002-7762-7042)
- Tom McGillivray
Institutions
- Twitter (United States) (US)
- Edinburgh Cancer Research (GB)
- University of Edinburgh (GB)
Publication Details
- Journal
- JACC CardioOncology
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1016/j.jaccao.2025.06.003
- Citations
- 3
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 4.16
Funders
- National Institute for Health and Care Research
- British Heart Foundation
- Efficacy and Mechanism Evaluation Programme